PrLZ expression is associated with the progression of prostate cancer LNCaP cells

Molecular Carcinogenesis

Volumn 48, Issue 5, 2009, Pages 432-440

  Li, Lei ^a   Zhang, Dong ^a   Zhang, Linlin ^a   Zhu, Guodong ^a   Sun, Yi ^b   Wu, Kaijie ^a   Wang, Xinyang ^a   He, Dalin ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b SHAANXI PROVINCIAL PEOPLE S HOSPITAL   (China)

Author keywords

Androgen independent; PrLZ; Progression; Prostate cancer

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; PRLZ PROTEIN; PROSTATE SPECIFIC ANTIGEN; TUMOR PROTEIN; UNCLASSIFIED DRUG; GELATINASE A; PRIMER DNA; TPD52 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CANCER GROWTH; CARCINOGENICITY; CELL INVASION; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PRLZ GENE; PROSTATE CANCER; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; DISEASE COURSE; ENZYMOLOGY; GENETICS; METABOLISM; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALIA;

ANIMALS; BASE SEQUENCE; DISEASE PROGRESSION; DNA PRIMERS; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM PROTEINS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 65649125632     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20481     Document Type: Article

References (36)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999;49:8-31, 31. (Pubitemid 9110790)
2. Zetter BR. The cellular basis of site-specific tumor metastasis. N Engl J Med 1990;322:605-612. (Pubitemid 20190796)
3. Wu TT, Sikes RA, Cui Q, et al. Establishing human prostate cancer cell xenografts in bone: Induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. Int J Cancer 1998;77:887-894.
4. Thalmann GN, Anezinis PE, Chang SM, et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994; 54:2577-2581.
5. Thalmann GN, Sikes RA, Wu TT, et al. LNCaP progression model of human prostate cancer: Androgen-independence and osseous metastasis. Prostate 2000;44:91 -103 Jul 101; 144(102)
6. Zhau HE, Li CL, Chung LW. Establishment of human prostate carcinoma skeletal metastasis models. Cancer 2000;88: 2995-3001. (Pubitemid 30413182)
7. Wang R, Xu J, Saramaki O, et al. PrLZ, a novel prostate- specific and androgen-responsive gene of the TPD52 family, amplified in chromosome 8q21.1 and overexpressed in human prostate cancer. Cancer Res 2004;64:1589-1594.
8. Boutros R, Fanayan S, Shehata M, Byrne JA. The tumor protein D52 family: Many pieces, many puzzles. Biochem Biophys Res Commun 2004;325:1115-1121.
9. Byrne JA, Tomasetto C, Garnier JM, et al. A screening method to identify genes commonly overexpressed in carcinomas and the identification of a novel complementary DNA sequence. Cancer Res 1995;55:2896-2903.
10. Byrne JA, Mattei MG, Basset P. Definition of the tumor protein D52 (TPD52) gene family through cloning of D52 homologues in human (hD53)and mouse(mD52). Genomics 1996;35:523-532. (Pubitemid 26270019)
11. Chen SL, Maroulakou IG, Green JE, et al. Isolation and characterization of a novel gene expressed in multiple cancers. Oncogene 1996;12:741-751.
12. Wang R, Xu J, Mabjeesh N, et al. PrLZ is expressed in normal prostate development and in human prostate cancer progression. Clin Cancer Res 2007;13:6040-6048.
13. Li L, He D, He H, et al. Overexpression of PML induced apoptosis in bladder cancer cell by caspase dependent pathway. Cancer Lett 2006;236:259-268.
14. He D, Mu ZM, LeX, et al. Adenovirus-mediated expression of PML suppresses growth and tumorigenicity of prostate cancer cells. Cancer Res 1997;57:1868-1872.
15. Chen PN, Chu SC, Chiou HL, Kuo WH, Chiang CL, Hsieh YS. Mulberry anthocyanins, cyanidin 3-rutinoside and cyanidin 3-glucoside, exhibited an inhibitory effect on the migration and invasion of a human lung cancer cell line. Cancer Lett 2006;235:248-259.
16. Zhau HY, Chang SM, Chen BQ, et al. Androgen-repressed phenotype in human prostate cancer. Proc Natl Acad Sci USA 1996;93:15152-15157.
17. Zhu G, Zhau HE, He H, et al. Sonic and desert hedgehog signaling in human fetal prostate development. Prostate 2007;67:674-684.
18. Sikes RA, Chung LW. Acquisition of a tumorigenic pheno- type by a rat ventral prostate epithelial cell line expressing a transfected activated neu oncogene. Cancer Res 1992;52: 3174-3181.
19. Kleiner DE, Stetler-Stevenson WG. Matrix metalloprotei- nases and metastasis. Cancer Chemother Pharmacol 1999; 43:S42-S51.
20. Cockett MI, Murphy G, Birch ML, et al. Matrix metallo- proteinases and metastatic cancer. Biochem Soc Symp 1998;63:295-313.
21. Kanoh Y, Akahoshi T, Ohara T, et al. Expression of matrix metalloproteinase-2 and prostate-specific antigen in localized and metastatic prostate cancer. Anticancer Res 2002; 22:1813-1817.
22. Morgia G, Falsaperla M, Malaponte G, et al. Matrix metal- loproteinases as diagnostic (MMP-13) and prognostic (MMP- 2, MMP-9) markers of prostate cancer. Urol Res 2005;33: 44-50.
23. Linja MJ, Visakorpi T. Alterations of androgen receptor in prostate cancer. J Steroid Biochem Mol Biol 2004;92:255-264. (Pubitemid 40128246)
24. Koivisto P. Aneuploidy and rapid cell proliferation in recurrent prostate cancers with androgen receptor gene amplification. Prostate Cancer Prostatic Dis 1997;1:21-25. (Pubitemid 127537060)
25. Koivisto P, Kononen J, Palmberg C, et al. Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997;57:314-319.
26. Cher ML, MacGrogan D, Bookstein R, Brown JA, Jenkins RB, Jensen RH. Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer. Genes Chromosomes Cancer 1994;11:153-162. (Pubitemid 24333390)
27. Macoska JA, Trybus TM, Sakr WA, et al. Fluorescence in situ hybridization analysis of 8p allelic loss and chromosome 8 instability in human prostate cancer. Cancer Res 1994;54:3824-3830.
28. Visakorpi T, Kallioniemi AH, Syvanen AC, et al. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res 1995;55:342-347.
29. ProuxV, Provot S, Felder-Schmittbuhl MP, Laugier D, Calothy G, Marx M. Characterization of a leucine zipper-containing protein identified by retroviral insertion in avian neuroretina cells. J Biol Chem 1996;271:30790-30797. (Pubitemid 26404099)
30. Zhang H, Wang J, Pang B, et al. PC-1/PrLZ contributes to malignant progression in prostate cancer. Cancer Res 2007; 67:8906-8913.
31. Kiefer JA, Farach-Carson MC. Type I collagen-mediated proliferation of PC3 prostate carcinoma cell line: Implications for enhanced growth in the bone microenvironment. Matrix Biol 2001;20:429-437.
32. Nagakawa O, Murakami K, Yamaura T, et al. Expression of membrane-type 1 matrix metalloproteinase (MT1-MMP) on prostate cancer cell lines. Cancer Lett 2000;155:173-179.
33. Richter E, Srivastava S, Dobi A. Androgen receptor and prostate cancer. Prostate Cancer Prostatic Dis 2007;10:114-118. (Pubitemid 46881662)
34. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001;61:3550-3555. (Pubitemid 32694958)
35. Wang J, Zhang H, Liang RX, et al. Identification and characterization of the novel human prostate cancer-specific PC-1 gene promoter. Biochem Biophys Res Commun 2007;357:8-13.
36. Luke MC, Coffey DS. Human androgen receptor binding to the androgen response element of prostate specific antigen. J Androl 1994;15:41-51. (Pubitemid 24061785)